Guardant Health Inc.'s genomic data-powered technologies for accelerating drug development infringe Tempus AI Inc.'s “groundbreaking” cancer research patents, according to a federal lawsuit.
Guardant’s analytical platforms copy Tempus AI’s patents covering methods to structure patient data for healthcare tools, use medical images to identify potential diseases, and employ artificial intelligence to analyze tissue images, Tempus AI said in a March 14 complaint filed in the US District Court for the Southern District of California.
The lawsuit claims at least four of Guardant’s products which analyze clinical and genomic data infringe US Patent Nos. 11,640,859; 12,112,839; 10,957,041; and 10,991,097.
“Tempus’ claims ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.